Syncona-backed Achilles Therapeutics recommends voluntary liquidation, return capital to shareholders
LONDON: Syncona Ltd, a leading life science investor, announced Monday that its portfolio company, Achilles Therapeutics plc, has recommended a members’ solvent voluntary liquidation to...
Syncona launches Beacon Therapeutics with £96 million financing to develop ophthalmic gene therapies
LONDON, UK: London-based healthcare company Syncona Ltd has announced the launch of Beacon Therapeutics Holdings Limited (Beacon Therapeutics), a leading ophthalmic gene therapy company. The...
Syncona invests £15mn in Oxford University spin out, OMass Therapeutics
LONDON, UK: Syncona Ltd it has committed £15 million in an oversubscribed £75.5 million Series B financing in OMass Therapeutics, a biotechnology company that identifies...
Novartis to buy Syncona’s Gyroscope Therapeutics for $1.5bn
LONDON, UK: Syncona Ltd has been reached to sell its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5 billion on a cash...
Syncona co-leads Series B financing in Quell Therapeutics of up to $156 million
LONDON, UK: Syncona Ltd has committed $25 million (£19 million) to Quell Therapeutics, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious...
Syncona’s Achilles announces additional financing plans including IPO in USA
LONDON: Syncona’s portfolio company, Achilles Therapeutics has announced that it expects to consider additional capital raising options this year, which could include an initial public...